All Oncology News

Przemyslaw W. Twardowski, MD, describes the available therapies for patients with advanced metastatic castration-resistant prostate cancer, including bone-targeted therapies; the work that still lies ahead with these treatments; and the challenges with finding biomarkers to help develop targeted agents.

The addition of pembrolizumab (Keytruda) to frontline platinum-based chemotherapy for advanced non–small cell lung cancer almost doubled the response rate compared with chemotherapy alone.

Howard M. Sandler, MD, sheds light on maximizing outcomes for patients with locally advanced prostate cancer, the evolving role of chemotherapy, and the steps to take once disease turns metastatic.

PARP inhibitors still have a place in the treatment paradigm of triple-negative breast cancer, but the role of these agents are significantly evolving.

Early results from a pre-planned interim analysis in the KEYNOTE-052 phase II trial of first-line pembrolizumab in cisplatin-ineligible patients with metastatic urothelial cancer demonstrated antitumor activity and a favorable response rate.

First-line therapy with nivolumab failed to improve progression-free survival in PD-L1 positive non-small cell lung cancer compared with standard chemotherapy.

A technically negative trial in high-risk adult soft tissue sarcoma nonetheless produced a significant survival benefit for anthracycline-based neoadjuvant chemotherapy.

Men with intermediate prostate cancer who received extreme hypofractionated radiotherapy reported a low incidence of side effects, with no significant differences compared with a similar cohort of men who received conventional fractionation after 2 years of treatment.

The FDA has granted a priority review designation to daratumumab (Darzalex) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.

A strategy to stimulate an immune response in radiation-damaged tumor cells resulted in preliminary evidence of activity—including longer survival—in a small clinical trial of patients with metastatic breast cancer.

The addition of external-beam radiotherapy to interstitial brachytherapy failed to reduce prostate cancer progression compared to brachytherapy alone in men with intermediate-risk disease.

Lori Rink, PhD, discusses the groundbreaking impact of imatinib (Gleevec) in gastrointestinal stromal tumors, the heterogeneity of the disease and its impact on personalizing treatment, and emerging therapies in the field.

As the FDA considers a supplemental biologics license application for 2 daratumumab-based triplet regimens in multiple myeloma, the results for 1 of the pivotal phase III studies supporting the sBLA have been published in The New England Journal of Medicine.

Tracey L. Evans, MD, shares her perspective on the role of PD-L1 testing in lung cancer. She also discusses the role of liquid biopsies and other assays that could possibly be on the horizon.

The Perlmutter Cancer Center at NYU Langone Medical Center has named noted clinician-scientist Kwok-Kin Wong, MD, PhD, as its new Chief of Hematology and Medical Oncology.

The total funding includes a National Cancer Institute award for more than $6 million that supports multidisciplinary prostate cancer research with goal of developing future drug therapies.

A Yale Cancer Center team completed a multi-institutional analysis of treatment options for patients with newly diagnosed EGFR-mutant non-small cell lung cancer with brain metastases to determine the best option for treatment.

Pooled data from ten universities finds added benefit from radiation boost among patients with negative margins following breast-conserving surgery.

William J. Gradishar, MD, discusses the need for new strategies that could alter the landscape of HR-positive breast cancer for the better, and how these methods can overcome drug resistance and delay disease progression.

Shaji Kumar, MD, discusses the roles that the recently released updated consensus criteria by the International Myeloma Working Group and MRD testing will play going forward in multiple myeloma.

Study results that examined patient-reported outcomes and quality of life measures demonstrate that hypofractionated radiotherapy is a viable, safe, and value-added alternative to patients with low-risk prostate cancer.

Hossein Borghaei, DO, provides additional insight on checkpoint inhibitors, determining patient selection, and how these therapies will continue to significantly impact the treatment landscape in non–small cell lung cancer for years to come.

In a recent study, a Yale Cancer Center team revealed that the addition of chemotherapy to postoperative treatment for adults with medulloblastoma improves survival.

The association between provider case volume and outcomes has long been suggested in cancer care.

The FDA has granted a breakthrough therapy designation to alectinib (Alecensa) as a frontline treatment for patients with ALK-positive non–small cell lung cancer.

In kidney cancer there are three “eras” in the history of treatment advances, said James Hsieh, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center.

Patients with head and neck cancer whose disease is associated with KRAS variant had significantly better progression-free survival and overall survival when treated with the monoclonal antibody cetuximab, according to findings of a retrospective analysis of a randomized trial.

Recent, promising data for androgen receptor antagonists could propel these agents into the treatment paradigm for a large subgroup of patients with triple-negative breast cancer.

Despite its substantial progress, much remains unknown about endocrine therapy as a treatment for breast cancer.

With several novel agents on the horizon, the treatment paradigm of triple-negative breast cancer is rapidly evolving and expanding its reach beyond the standard approaches.